Quote | Cyteir Therapeutics Inc. (NASDAQ:CYT)
Last: | $3.02 |
---|---|
Change Percent: | -0.33% |
Open: | $3.03 |
Close: | $3.02 |
High: | $3.09 |
Low: | $3 |
Volume: | 1,006,884 |
Last Trade Date Time: | 03/15/2024 03:00:00 am |
News | Cyteir Therapeutics Inc. (NASDAQ:CYT)
2023-03-23 16:44:01 ET Cyteir Therapeutics press release ( NASDAQ: CYT ): Q4 GAAP EPS of -$0.25. Cash and cash equivalents as of December 31, 2022 were $147.1 million, which are expected to fund planned operations into 2026. For further details see: Cyteir Therap...
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Message Board Posts | Cyteir Therapeutics Inc. (NASDAQ:CYT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CYT News Article - Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Finan | whytestocks | investorshangout | 03/23/2023 8:05:48 PM |
Shareholders need to get John Thero off the | raistthemage | investorshub | 01/31/2023 7:16:06 PM |
whytestocks: $CYT News Article - Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice Presiden | whytestocks | investorshangout | 05/03/2022 7:30:59 PM |
whytestocks: $CYT News Article - Cyteir Therapeutics Announces the Appointment of John F. Thero to B | whytestocks | investorshangout | 02/07/2022 1:10:48 PM |
whytestocks: $CYT News Article - Cyteir Therapeutics Reports Third Quarter 2021 Financial Results an | whytestocks | investorshangout | 11/12/2021 1:40:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
NASDAQ Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...